ADMA Biologics Stock (NASDAQ:ADMA)
Previous Close
$22.62
52W Range
$3.60 - $23.63
50D Avg
$18.12
200D Avg
$11.47
Market Cap
$5.31B
Avg Vol (3M)
$5.27M
Beta
0.65
Div Yield
-
ADMA Company Profile
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
ADMA Performance
Peer Comparison
Ticker | Company |
---|---|
PLRX | Pliant Therapeutics, Inc. |
SANA | Sana Biotechnology, Inc. |
BCRX | BioCryst Pharmaceuticals, Inc. |
XFOR | X4 Pharmaceuticals, Inc. |
AKBA | Akebia Therapeutics, Inc. |
ATRA | Atara Biotherapeutics, Inc. |
FATE | Fate Therapeutics, Inc. |
RCUS | Arcus Biosciences, Inc. |
STOK | Stoke Therapeutics, Inc. |
MCRB | Seres Therapeutics, Inc. |
TNXP | Tonix Pharmaceuticals Holding Corp. |
CRBU | Caribou Biosciences, Inc. |
ANTX | AN2 Therapeutics, Inc. |
ACLX | Arcellx, Inc. |
TFFP | TFF Pharmaceuticals, Inc. |
ETNB | 89bio, Inc. |
VXRT | Vaxart, Inc. |
ANEB | Anebulo Pharmaceuticals, Inc. |
CDTX | Cidara Therapeutics, Inc. |
INMB | INmune Bio, Inc. |
MDGL | Madrigal Pharmaceuticals, Inc. |